Keyphrases
Non-muscle Invasive Bladder Cancer (NMIBC)
100%
Blue Light Cystoscopy
100%
Microeconomics
100%
Hexaminolevulinate
66%
Cystoscopy
50%
Clinical Practice Guidelines
33%
Clinic Setting
33%
White Light Cystoscopy
33%
Cancer Patients
16%
Advanced Technologies
16%
Working Diagnosis
16%
Newly Diagnosed
16%
Bladder Cancer
16%
Recurrence Rate
16%
Improved Patient Outcomes
16%
Tumor Stage
16%
Tumor Grade
16%
Medicare Reimbursement
16%
Reimbursement Rates
16%
Relative Risk Reduction
16%
Recurrence Risk
16%
Diagnostic Ratios
16%
Cost Impact
16%
Facility Costs
16%
Cost-effective Care
16%
Budget Impact
16%
Budget Impact Model
16%
Clinical Input
16%
Medicine and Dentistry
Cystoscopy
100%
Non Muscle Invasive Bladder Cancer
100%
Health Care Cost
63%
Aminolevulinic Acid Hexyl Ester
36%
Recurrent Disease
27%
Medicare
9%
Bladder Cancer
9%
Cancer Staging
9%
Clinical Guideline
9%
Relative Risk Reduction
9%
Option Value
9%
Nursing and Health Professions
Non Muscle Invasive Bladder Cancer
100%
Cystoscopy
100%
Aminolevulinic Acid Hexyl Ester
36%
Hospital
27%
Recurrent Disease
27%
Medicare
9%
Practice Guideline
9%
Reimbursement
9%
Treatment Outcome
9%
Bladder Cancer
9%
Cancer Staging
9%
Clinical Guideline
9%
Pharmacology, Toxicology and Pharmaceutical Science
Non Muscle Invasive Bladder Cancer
100%
Aminolevulinic Acid Hexyl Ester
100%
Recurrent Disease
75%
Bladder Cancer
25%
Cancer Staging
25%